In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cleveland Clinic Innovations – Creating A Global Innovation Engine

Executive Summary

At a time when venture capital dollars are scarce and US-based innovation is threatened, Cleveland Clinic Innovations, with its novel GCIC cardiovascular project, is bringing critical mass and a new direction to an inherently unwieldy process.

You may also be interested in...



Deals Of The Week Watches An Unlikely HCIT Partnership: GSK & Community Care of North Carolina

GSK and CCNC, a non-profit network of health care providers, are developing a medication management analytics system that could get them into the health care IT business. For GSK, the main goal is to learn about changing dynamics of health care delivery systems, in a venture that is entirely independent of the company’s core drug business.

How The Midwest Was Won: Creating A New Epicenter For Device Innovation And Investment

Talent, innovation, world-class research institutions, established supply chains, and a lower cost of doing business – what else do you need to launch and grow a device company? Well, capital, for one. Players in the Midwest are working in a variety of ways to draw entrepreneurs and venture money to the region, and their efforts are reaping positive results.

In Medical Devices, Is "Good Enough" Good Enough?

Device companies have historically been rewarded for even incremental technology enhancements with premium pricing by a price-insensitive customer, all in the spirit that no improvement to the clinical episode would go unrewarded. But in a health care system that is trying to balance exploding costs and greater access, such a goal becomes simply unaffordable. Instead, payors, hospitals and even physicians, encouraged by government policy makers, will increasingly look for technology that delivers an acceptable clinical outcome at a better price.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003880

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel